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ABSTRACT
The Mark II molybdenum-99/technetium-99m generator now supplied to
hospitals by the Australian Atomic Energy Commission is a non-sterile elution
system. The Mark III version will be supplied as a sterile elution system.
A validation study has been undertaken to assess the capability of the
new production facility, to evaluate up-to-date procedures for manufacturing
sterile generators and to demonstrate that a sterile radionuclide generator
can be made.
(Continued)
Generator manufacturing procedures and a time study of the validation are
described. Microbiological methods for monitoring in-process aspects of
manufacture, disinfectant efficacy and generator sterility are defined.
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describe the subject content of this report for information retrieval
purposes. For further details please refer to IAEA-INIS-12 (INIS: Manual for
Indexing) and IAEA-INIS-13 (INIS: Thesaurus) published in Vienna by the
International Atomic Energy Agency.
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1. INTRODUCTION
The AAEC Mark II inolybdenuin-99/tecnrietiuni-99ni generator is now supplied
to hospitals by the Australian Atomic Energy Commission [AAEC 1972]. The
generator is loaded by remote handling and then assembled in a normal
laboratory environment. Manufacturing procedures have been designed to
minimise microbiological contamination to each unit, and routine laboratory
tests have shown that untreated eluates are often sterile. However, the Mark
II design generator is supplied to the customer as a non-sterile elution
system.
The AAEC Mark III generator has been designed and will be supplied as a
sterile elution system comparable with other systems on the market.
A validation study of the in-cell manufacture and the aseptic assembly of
the Mark III generator was undertaken to assess the capability of the new
production facility and to evaluate the up-to-date procedures required to
produce sterile generators. The validation study involved the assembly of
fifty non-radioactive generator units by each of four selected operators.
After assembly and test elution, the units were incubated and the contents
tested for sterility.
2. GENERATOR IN-CELL MANUFACTURE AND ASEPTIC ASSEMBLY
2.1 Generator Component^
For the validation study, Mark III generators were manufactured from the
following components. These components were assembled in stages to complete a
generator unit (Figure 1).
Generator vial
This component consists of a double ended glass vial containing a
sintered glass frit base. A 1.5 g alumina column was placed on the frit and
secured by quartz wool. Vials were subsequently packed in units of ten in a
stainless steel container, covered with a loose fitting lid, and sterilised in
an oven at 160°C for a minimum of 4 hours.
Elation pipev/ork
Sterile and pyrogen-free elution pipework was purchased. During in-cel?
manufacture, a unit was secured by remote handling to each vial opening (stage
1). To facilitate the in-cell operation, the units were aseptically removed
from their sterile sachets and packed in groups of twenty in stainless steel
containers which had been pre-sterilised at 160°C for a minimum of 4 hours.
Dispenser unit
The dispenser unit consists of a section of silicone rubber tubing
connected to a piece of dispenser tubing. Covers were secured at each end and
the entire assembly was sterilised by irradiation at an integrated gamma dose
of 25 kGy. During aseptic assembly, the end of the attached silicone rubber
tubing was connected to the downstream elution pipework unit (stage 2).
Charcoal filter unit
A 16 gauge by 1 in. stainless steel needle was connected to a charcoal
filter unit. A cover was secured to the remaining end and the entire assembly
sterilised at 25 kGy (stage 3). During aseptic assembly, the unattached end
was connected to the upstream elution pipework unit.
0.9 per cent saline bag
Sterile and pyrogen-free isotonic (0.9 per cent) sodium chloride solution
was purchased in 250 mL vinyl bags. A 1 ml aliquot of sterile distilled water
was used to simulate the aseptic addition of chemicals needed to increase the
elution efficiency of the generators.
2.2 Conditions of Validation
Staff performing the in-cell manufacture and aseptic assembly were
trained in accordance with the procedures outlined by Saunders [1981] and
prescribed by the Australian Department of Health [DOH 1976].
On commissioning, the manufacturing facility was cleaned and sanitised, a
task subsequently performed once £->.r week in accordance with procedures
outlined by Davis and Saunders [1980].
New equipment was used throughout the trial, with the exception of twenty
generator cases and twenty lead pots that had been commissioned at the
beginning and re-used throughout the validation. The equipment was
disinfected with sterile sponge wipers saturated in either a solution of 0.5
per cent chlorhexidine gluconate (Hibitane:ICI Aust. Ltd) and 70 per cent
isopropyl alcohol, or a mixture of 2.0 per cent quarternary ammonium (Award:
Diversey (A/Asia) Pty Ltd) and 70 per cent isopropyl alcohol, and then stored
in airtight containers.
The disinfectants, which were alternated monthly, were prepared as a 70
per cent isopropyl alcohol :water base, dispensed in 500 mL aliquots,
sterilised by irradiation (25 kGy), and then activated by passing the
appropriate volume of Award or Hibitane through a 0.45 ym Mil lex (Millipore
Pty Ltd) filtration unit.
2.3 Manufacturing Procedure
The non-radioactive Mark III generator was manufactured in two stages.
The first stage comprised loading, saline washing, sealing and autoclaving the
generator vials within lead cells flushed with filtered air under positive
pressure.
The second stage involved the transfer of generator vials to lead
shielding containers, insertion of these containers into generator carriers,
connection of components, and test elution of the units; this stage was
performed inside a room supplied and flushed with filtered air under positive
pressure. Assembly and test elution of each unit was conducted inside a clean
work station located within this environment. In stages 1 and 2, the air used
to flush the lead cells and assembly room was passed initially through 0.2 \im
filters.
Transfer of autoclaved generators from the cell area to the final
assembly and elution area was effected by a mobile lead cell. Use of this
cell enabled operators to place the vials inside lead containers by remote
handling. An overhead crane was used to lower each lead container into a
generator carrier, and a stainless steel trolley to transfer the generator
carrier to the clean air unit.
2.3.1 In-cell manufacture
The first stage of manufacture, performed in Cell 1 (Figure 2), involved
the removal of residual calcium hypochlorite solution from in-cell wash lines.
This was effected by emptying and purging each line with 70 mL of sterile 0.9
per cent sodium chloride solution (saline). Peristaltic pumps housed in a
clean air unit within the manufacturing facility extracted the saline from
sterile containers and passed this solution via vinyl tubing to the Cell 1
wash lines. A 3 ml aliquot of saline was then sampled from each line into a
sterile 30 ml Wheaton vial and monitored for the level and type of
microorganisms present.
Sterile generator vials were transported to the first manufacturing cell
and placed on a turntable, where they were loaded by pipette with 1 ml of
sterile 1 M nitric acid. They were then transferred to wash stations, rinsed
with 250 mL of sterile saline and passed to a second cell where each vial was
secured at both ends with an elution pipework unit, placed in an autoclave and
held at 115°C (-0°C, +4°C) for thirty-five minutes. Two biological monitors
were included with each autoclave load (Figure 3).
2.3.2 Aseptic assembly
Two operators were required for the assembly operations. The first was
responsible for the transfer of generator vials to lead containers, insertion
of these containers into generator carriers, and transportation of the
carriers to the second operator who performed the cleaner stages of component
assembly and test elution. Because of the critical nature of these tasks,
operators were assigned to and remained with specific operations for the
duration of assembly.
After autoclaving, the generators were transferred by remote handling to
lead containers, previously disinfected by procedures outlined in Section 2.2.
Each container was transferred by overhead crane to a sanitised generator
carrier secured on a stainless steel trolley and transported to the laminar
flow cabinet for final assembly and test elution. During this time, the
second operator placed inside the clean air unit the components required for
aseptic assembly. On receipt of the generator carrier, this operator
assembled the generator in the following manner.
Rubber septums as part of the saline bag and two test elution vials were
swabbed with sterile 70 per cent isopropyl alcohol. The 16 gauge x 1 in.
needle on the charcoal filter unit, was inserted into a saline bag septum
(stage 3).. and the Luer connection at the opposite end of the filter connected
to the upstream generator milking lead (stage 4).
The downstream generator milking lead was then connected to a metal
needle on the dispenser unit. A sterile 19 gauge x 1.5 in. needle was
attached to the dispenser unit outlet and the generator eluted into a sterile
evacuated 10 ml Wheaton vial (stage 5). The generator was eluted a second
time into a sterile evacuated 10 mL Wheaton vial containing a pellet of
tryptone soya broth (Oxoid Aust. Pty Ltd).
Ten generators were manufactured in each batch. Of these, nine were
eluted with normal saline and the tenth, prepared at random, was purged with
either sterile fluid thioglycollate medium or sterile tryptone soya broth
(both supplied by Oxoid Aust. Pty Ltd).
Where full test eluates of the assembled unit were unattainable, the
units were tested as follows:
(i) For leakages due to faulty connections and parts, the generators
were eluted to yield the maximum possible eluate.
(ii) If generator vials were broken through in-cell handling, crimping or
autoclaving, or generator leads were broken due to mobile cell
handling, an assembly was simulated and the generator by-passed.
The assembled generators were then removed from the lead containers and
incubated at 37°C until the test was completed.
After completion of each daily operation, the facility and components
were sanitised in preparation for the next batch. In addition, the wash lines
were filled with calcium hypochlorite solution containing a minimum 1000
yg mL of chlorine contained in a saline solution at pH 6.0 - 6.5 [Farrington
1980].
2.4 Time Study
The time taken to perform each stage of manufacture was assessed for the
following conditions:
Stage 1 Preparation of ten inactive generators to the autoclave stage
of manufacture.
Stage 2 Assembly and test elution of ten inactive generators.
Stage 3 Preparation of the manufacturing facility and component parts
for an assembly of ten units.
Table 1 shows the time taken by four operators to complete each stage. These
times represent composite work activity. Stage 1 would take longer if it were
performed by one operator.
The following operations, normally followed during manufacture of
radioactive generators, were excluded from the validation trial.
(i) Commissioning lead pots and generator cases from bulk storage
facilities and their disinfection and storage in the generator
manufacturing facility - approximately one hour for ten units.
(ii) Disinfection of molybdenum-99 stock solution in Cidex (Johnson and
Johnson Pty Ltd) - approximately 30 minutes.
(iii) Loading and holding molybdenum-99 solution for thirty minutes on
the alumina column - approximately forty minutes for ten units.
(iv) Calibration and measurement of generators - approximately thirty
minutes for ten units.
3. MICROBIOLOGICAL MONITORING
3.1 Biological Indicators
Two biological indicators were included in each autoclave cycle. The
monitors, prepared from paper strips impregnated with sufficient numbers of
Bacillus stearothermophi'1 us spores to survive for five minutes at 121°C, were
contained in a sterile Mark III generator vial, secured at each end with a
sterile rubber closure and aluminium seal. Each monitor in a pair was
prepared differently for autoclaving and testing, as is described below.
The twenty autoclave cycles monitored during validation successfully
destroyed the Bacillus stearothermophilus spores contained in both types of
biological indicator.
3.1.1 Type A monitor
For the type A monitor, spore strips were placed aseptically inside a
sterile 1.5 g alumina column secured by sterile quartz wool (Figure 3).
Twenty minutes before heat treatment, the column was purged with 10 mL sterile
water for injection. Excess water was removed by passing air into the column
via a 0.45 \im Mil lex filter unit.
After heat treatment, the monitor was filled with sterile tryptone soya
broth and incubated at 56 ± 2°C for a minimum of 14 days. The eluate was then
transferred to a sterile vial containing 10 mL tryptone soya broth, incubated
for a further 4 days and examined for Bacillus stearothermophilus.
3.1.2 Type B monitor
For the type B monitor, spore strips were placed aseptically inside a
sterile Mark III generator vial and within 20 minutes of heat treatment the
vial was filled with tryptone soya broth (Figure 3). Following heat
treatment, the vial was incubated at 56 ± 2°C for a minimum of four days and
examined for Bacillus stearothermophilus.
3.1.3 Control monitor
An untreated type B monitor, filled with tryptone soya broth and
incubated at 56 ± 2°C, was used to monitor the efficacy of the procedure.
3.2 Wash Lines
A 3 mL aliquot of saline was removed from each wash line into a sterile
30 mL Wheaton vial. This solution was passed through a 0.45 ym Swinnex
filtration unit (Millipore Pty Ltd), the filter removed, placed in a Petri
dish containing tryptone soya agar incubated at 32 ± 2°C for a minimum of
three days, and inspected for microbiological contamination. No
microbiological contamination was detected in the 18 samples monitored during
validation.
3.3 Air Monitoring
During validation, the environment was monitored daily by the exposure of
agar plates. The plates were prepared in a clean air unit and stored in a
sterile container until required; the gel surface was moistened with 1 ml
tryptone soya broth before exposure. The procedure involved the exposure of
Petri dishes, containing tryptone soya agar, for four hours between 1000 and
1400 hours, followed by incubation at 32 ± 2°C for a minimum of three days.
The outer surfaces of plates used to monitor in-cell environments were
protected from radioactive contamination by sterile plastic covers.
Exposure plates were sited at the following numbered locations (Figure
4):
(•I) The Anteroom
!_. Shelf above the conveyor outlet 3_. Centre front middle shelf
2_. Centre front top shelf 4_. Centre front bottom shelf
5_. Centre front underbench area
(ii) The_Manufacturing Faci 1 ity
1. Right front of bench 7. Centre of Cell 2
2. Centre front of bench 8. Centre of Cell 1
3. Left front of bench 9. Centre of clean air unit
housing wash lines
4. Shelf adjacent to anteroom door 10. Centre of the clean air unit
used to assemble generators
5. Centre front of Cells 3 and 4 11. Right upper section of
conveyor
6. Centre front of Cells 1 and 2 12. Middle upper section of
conveyor
13. Upper section of conveyor
Table 2 shows the mean and range values of the number of colonies detected at
the various locations.
3.4 Disinfectant Monitoring
3.4.1 In-use disinfectant solutions
During validation, in-use disinfectant solutions were monitored
periodically for microbiological contamination. A 10 ml aliquot from each
container was passed through a 0.45 urn Swinnex filtration unit, the filter
washed twice with 10 ml sterile normal saline, removed and placed in a Petri
dish containing tryptone soya agar, incubated at 32 ± 2°C for a minimum of
three days, and inspected for microbiological contamination. No
microbiological contamination was detected in the samples monitored during
validation.
3.4.2 Efficacy of disinfectant solutions
During commissioning, the efficacy of mixtures of 0.5 per cent
chlorhexidine gluconate or 2.0 per cent quarternary ammonium with 70 per cent
ethyl alcohol, a mixture of 1:60 vol./vol. Formula 51 (Reckitt and Colman
Aust. Ltd) with water, and 70 per cent isopropyl alcohol, was determined
against microorganisms isolated from the manufacturing system.
Forty-eight isolates were purified, identified for genus [Bennett 1960;
Cowan and Steel 1970; Buchanan and Gibbons 1974; Analytab 1977] and tested
for resistance to the disinfectants.
Four Petri dishes, each containing tryptone soya agar, were prepared with
a lawn of each type of organism. A filter disc containing 0.05 ml of the
selected disinfectant was placed in the centre of each lawn, the plate
refrigerated for 30 minutes to allow diffusion of the disinfectant, incubated
at 32 ± 2°C for three days, then inspected for the presence of a zone of
inhibition around each filter.
All isolates were sensitive to the 70 per cent ethyl alcohol and water
based mixtures. Most isolates displayed reduced sensitivity, and many
indicated resistance to 70 per cent isopropyl alcohol. Sixteen of the least
sensitive organisms were tested against 70 per cent isopropyl alcohol
containing either 0.5 per cent chlorhexidine gluconate or 2.0 per cent
quarternary ammonium; they displayed a sensitivity similar to that of the
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ethyl alcohol based disinfectants. Consequently, the disinfectants selected
to sanitise the facility and components during validation were 0.5 per ce'tt
chlorhexidine gluconate in 70 per cent isopropyl alcohol and 2.0 per cent
quarternary ammonium in 70 per cent isopropyl alcohol.
3.5 Sterility Testing
Media used to test the sterility of assembled generators were prepared in
accordance with methods outlined in Appendix C of the Australian Code of Good
Manufacturing Practice for Therapeutic Goods [DOH 1976]. Liquid media were
used within eight weeks of manufacture.
They were tested for sterility by incubating all vessels at 20 to 25°C
for a minimum of nine days, having first been tested for ability to support
growth by reconstituting two vessels from each batch with the appropriate
volume of sterile normal saline containing the respective microorganisms.
Vessels of fluid thioglycollate media were inoculated with either 100
viable spores of Clostridium sphenoides ATTC 19403, or 100 viable cells of
Staphylococcus aureus ATTC 6538P, incubated at 32 ± 2°C, and inspected for
growth after 24 hours.
Vessels of tryptone soya broth were inoculated with either 100 viable
spores of Bacillus subtil us ATCC 11774 or 100 viable cells of Candida albicans
ATCC 10231 incubated, respectively, at 36 ± 2°C and 23 ± 2°C and inspected for
growth after 24 hours.
Evacuated vials, each containing a pellet of tryptone soya broth, were
prepared and pretested by reconstituting, inoculating and incubating four
vials in the above manner. The vials were stored at 20 to 25°C and used
before the six month expiry date.
3.5.1 Sterility testing of eluates
During aseptic assembly, nine eluates from each run were prepared by
priming the generator with normal saline and eluting into a sterile evacuated
10 ml Wheaton vial containing a pellet of tryptone soya broth. The tenth,
eluate was obtained by priming the generator with either fluid thioglycollate
medium or tryptone soya broth and eluting into a sterile evacuated 10 ml
Wheaton vial.
11
The fluid thioglycollate vial and alternative reconstituted tryptone soya
broth vials were incubated at 32 ± 2PC, and the remaining reconstituted
tryptone soya broth vials were incubated at 23 ± 2°C for a minimum of 14 days.
On completion of incubation, the vials were inspected for turbidity and a
stasis test was performed on one vial from each group by inoculating 10 to 20
and no more than 110 organisms of the appropriate microbe, incubating the vial
at the appropriate temperature for a further 24 to 48 hours, and inspecting
the vessel for turbidity. A validated sterility test was obtained for all
units tested in this manner.
All generators passed this sterility test; a total of 193 of the 200
units tested were fully assembled units. Of the remaining seven units,
eluates were obtained from five generators which were incomplete because
either the generator vial or the elution pipework unit was broken. The
eluates obtained from these units passed the sterility test. The remaining
two units could not be tested for sterility because of a mechanical defect in
the generator assembly.
3.5.2 Sterility testing of assembled generators
After assembly, generators primed with either fluid thioglycollate medium
or tryptone soya broth were incubated, respectively, at 32 ± 2°C and 23 ± 2°C
for a minimum of 14 days. At the end of the incubation period, each vessel
was eluted into an evacuated 10 mL Wheaton vial and the generator system and
eluate examined for turbidity. A stasis test was performed on each generator
system in accordance with the methods described in Section 3.5.1. A validated
sterility test was obtained for all units treated in this manner.
Generators primed with normal saline were held at 36 ± 2°C for a minimum
of 24 hours. After incubation, a sterility test was performed by eluting
duplicate 80 mL aliquots from each unit into two vessels each containing 10
per cent of 11 times concentrated tryptone soya broth and duplicate 45 mL
aliquots were eluted into two vessels each containing 50 per cent of a twice
concentrated fluid thioglycollate medium.
A saline bag incorporating an elution lead, sterilised by irradiation at
50 kGy, was included with each group of nine units to monitor the operators'
technique, the reagents and the facility.
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The two fluid thioglycollate vessels were incubated at 32 ± 2°C; one
tryptone soya broth vial was incubated at 36 ± 2°C and the other at 23 ± 2°C
for a minimum of 14 days. At the end of incubation, the vessels were
inspected for turbidity and a stasis test performed on a minimum of one vial
from each series of incubations in accordance with the methods outlined in
Section 3.5.1. A total of 191 completely assembled generators passed this
sterility test.
The remaining nine sterility tests were performed on incomplete generator
systems. Six of the systems were incomplete and missing the generator
vial/elution pipework unit which, in five cases, was damaged during
manufacture and assembly and, in the sixth case, seized and would not allow
liquid to pass. The remaining three systems contained filters which had
seized during incubation and had to be removed for testing to proceed.
4. DISCUSSION AND CONCLUSIONS
This study was undertaken to assess the capabi l i ty of the new production
fac i l i ty and up-to-date procedures for the manufac ture of sterile radionucl ide
generators. Rout ine manufacture of such a system w i l l enable the AAEC to
supply a r ad ionuc l ide e lu t ion system of a qual i ty comparable to those produced
by its competitors.
The generators were manufac tured in two stages. The f i rs t stage, which
comprised l o a d i n g , w a s h i n g , sea l ing and au toc lav ing of the generator v i a l s ,
was performed inside lead cells f lushed wi th air under posit ive pressure. The
second stage, which involved transfer of generator v i a l s to lead s h i e l d i n g
containers, insertion of these containers into generator carriers, connection
of components and test e lu t ion of the uni ts , was performed ins ide a clean work
station, situated w i t h i n a room f lushed wi th fi l tered air.
The va l ida t ion study required t r a in ing of four operators in aseptic
procedures, assessment of the efficacy of the proposed disinfectants , a
comprehensive environmental study on the fac i l i ty , and sterility tests of the
manufactured uni ts .
Each operator prepared fifty non-radioactive generators in batches of ten
per day. Of these, n ine were f lushed wi th sterile isotonic sa l ine and the
tenth with sterile microbiological media. A sterility test was performed on
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the first eluate and the entire contents of each generator.
All units prepared during the validation study passed the prescribed
criteria for sterility, thus substantiating the claim that the new production
facility and procedures can routinely support the manufacture of a sterile
radionuclide generator.
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TABLE 1
TIME STUDY OF ASSEMBLY OF MARK III GENERATORS
Time Taken by Each Operator
Operator*/Run
Operator 1
Run 1
2
3
4
5
Operator 2
Run 1
2
3
4
5
Operator 3
Run 1
2
3
4
5
Operator 4
Run 1
2
3
4
5
Stage 1
h/min
1 30
1 30
1 30
1 15
1 10
1 45
1 30
2 15**
1 45
1 20
1 30
1 35
1 30
1 30
1 15
1 30
1 30
1 15
1 30
1 30
Stage 2 Stage 3
h/mi n h/mi n
2 15 1 00
1 45 1 00
1 25 45
1 20 45
1 25 35
2 00 1 00
1 45 1 00
2 00 1 00
1 45 45
1 30
2 00
1 30
1 30
1 30
1 30
1 45
1 25
1 15
1 25
1 10
* Each main operator was assisted by another operator
** Completed by one operator only
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TABLE 2
RESULTS FOR AGAR PLATES EXPOSED IN MARK III GENERATOR
ANTEROOM AND MANUFACTURING FACILITY
Position Number of
Exposures
Anteroom
Conveyor Shelf
Top Shelf
Middle Shelf
Bottom Shelf
Underbench
Manufacturing Facility
Right Side Bench
Centre Bench
Left Side Bench
Anteroom Doors
Cells 3 and 4
Cells 1 and 2
Centre Cell 2
Centre Cell 1
Clean Air Unit - Wash Lines
Clean Air Unit - Assembly
Right Side Conveyor
Middle Conveyor
Left Side Conveyor
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
Colonies Per Four
Hour Exposure
Mean
16
1
1
2
3
1
2
1
2
2
5
0
0
0
0
4
1
2
Range
0-47
0-18
0-6
0-14
0-46
0-14
0-16
0-4
0-10
0-7
0-25
0-1
0-2
0-8
0-1
0-16
0-5
0-12
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Prepared in cell environment
STAGE 1
Connections of elation
pipework
Prepared in clean air unit
STAGE 2 STAGES 3 and 4
Connection of Connection of charcoal
dispenser unit f i l ter and saline bag
i4~Quartz
wool
•Alumina
Frit
Generator
column
Silicone rubber
tubing unit
i-i
I )
Saline bag
Dispenser
tubing unit
FIGURE 1. STAGES IN THE ASSEMBLY OF A
MARK III GENERATOR
Dispensing station/ ,Wash lines Autoclave rimping station
Celt 1 inn »Turntable connecti g
Cells 1 & 2
Clean Air Unit :
housing pumps used
to purge in-cell
wash lines
s'x'x'xVx'x'x'x'x'x'J
• ~
Mobile Cell :
used to transport
generators from
in-cell manufacture
to aseptic assembly
stage
co
Clean Air Unit :
used to aseptically
assemble stages 2~5
of Mk TTi generator
manufacture
FIGURE 2. M A R K II I GENERATOR M A N U F A C T U R I N G FACILITY
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Quartz wool
Spore strips imbedded
in alumina column
TYPE A MONITOR
Spore strips contained
tryptone soya broth
during heat treatment
TYPE B MONITOR
F I G U R E 3. BIOLOGICAL INDICATORS USED TO MONITOR THE
STERILISATION OF M A R K III GENERATOR COLUMNS
FIGURE 4. LOCATION OF AIR EXPOSURE PLATES IN M A R K III GENERATOR
ANTEROOM AND M A N U F A C T U R I N G F A C I L I T Y
(exposure plate positions are identified in Section 3.3)
